Partner Content Partner Content Beyond Immunotherapies Latest innovations emerging from immunotherapy research
Partner Content Partner Content Managing Multi-Arm Studies in an Evolving Immuno-Oncology La... Collaborate with CROs and sites to help minimize risks
Partner Content Partner Content Orphan medicines, advances, access and affordability LONDON, UNITED KINGDOM, April 19th 2017:
Views & Analysis The top three benefits to commercial outsourcing in pharma In the face of continuing industrial and technological progress – and the resulting imperative for business agility – commercial outsourcing has come of age not a moment too soon.
White Papers Sponsored Seizing the potential of commercial outsourcing in the pharm... The power and potential of outsourcing has long been recognised as a core enabler of business growth.
Views & Analysis Getting it right: the UK’s pathway for 2017 The implications for global pharma HQs and what the UK needs to do.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.